GABAPENTIN
It is a valuable adjunct to othr anti-epileptic drugs in adult patients who have not achieved adequate control of partial seizures with these agents used alone or in combination. It has a simple pharmacokinetic profile and is not protein bound.Adjunctive therapy in the treatment of partial seizures with secondary generalisation. It is particularly useful in controlling secondarily generalised tonic-clonic seizures.
900-1800 mg per day in three divided doses to a maximum of 2400 mg per day. Titation of dose: 300 mg on day one, 300 mg b.i.d. on day two, and 300 mg t.i.d. on day three.
Hypersensitivity.
Should not discontinue abruptly. Paediatrics: Not recommended. Pregnancy: Should be used only if the potential benefit justifies the potential risk to the fetus. Lactation: Use only, if benefits clearly outweighs the risks.
Somnolence, ataxia, fatigue, headache, nausea, dizziness, tremor, diplopia and nystagmus.
Cimetidine decreases clearance of gabapentin. Antacids may reduce bioavailability of gabapentin.
